Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roducitabine - Ocuphire Pharma

X
Drug Profile

Roducitabine - Ocuphire Pharma

Alternative Names: FCPEC; Fluorocyclopentenylcytosine; NGC-Gemcitabine; PCS-3117; RX 3117; TV-1360

Latest Information Update: 05 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Developer Ocuphire Pharma; Processa Pharmaceuticals; Rexahn Pharmaceuticals
  • Class Antineoplastics; Cyclopentanes; Fluorinated hydrocarbons; Nucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 29 Nov 2023 Processa Pharmaceuticals expects discussion with FDA for phase IIb/IIIa trial in first half of 2024
  • 07 Sep 2023 Phase-II clinical trials in Solid tumours in USA (PO)
  • 05 Apr 2023 Processa Pharmaceuticals plans to discuss with the US FDA regarding the design of phase IIB trial and Project Optimus, in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top